Neurology
Perspective | Will unpredictable side effects dim the promise of new Alzheimer’s drugs?
8 Aug, 2023 | 13:30h | UTCWill unpredictable side effects dim the promise of new Alzheimer’s drugs? – Science (a few articles per month are free)
Related:
RCT | Donanemab slows early symptomatic Alzheimer’s progression, but raises serious safety concerns
RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns
Review | Treatment of pediatric convulsive status epilepticus
4 Aug, 2023 | 11:42h | UTCTreatment of pediatric convulsive status epilepticus – Frontiers in Neurology
RCT | Recombinant human prourokinase demonstrates noninferiority to alteplase in acute ischemic stroke treatment
3 Aug, 2023 | 13:46h | UTCSee also: Visual Abstract
Study | Frequent soccer heading linked to cognitive impairment risk in retired players
3 Aug, 2023 | 13:12h | UTCInvited Commentary: Heading Frequency and Risk of Cognitive Impairment in Retired Male Professional Soccer Players – JAMA Network Open
Related:
Dementia risk in former professional footballers is related to player position and career length.
Study: Neurodegenerative Disease Mortality Increased Among Former Professional Soccer Players
Commentary on Twitter
In retired professional UK soccer players, repetitive heading was linked to an increased risk of cognitive impairment later in life by >2x (6-15/match) and >3x (>15x/match). https://t.co/lV2xNa1TTR
— JAMA Network Open (@JAMANetworkOpen) July 17, 2023
Review | Diagnosing delirium in perioperative and intensive care medicine
3 Aug, 2023 | 13:09h | UTCDiagnosing delirium in perioperative and intensive care medicine – Current Opinion in Anesthesiology
RCT | Multiple sclerosis disease-modifying therapy continuation versus discontinuation in older individuals
2 Aug, 2023 | 14:00h | UTCRisk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial – The Lancet Neurology (link to abstract – $ for full-text)
Commentaries:
Discontinuing Multiple Sclerosis Therapies at Age 55 or Older – NEJM Journal Watch
RCT | Atogepant outperforms placebo in reducing migraines over 12 weeks
2 Aug, 2023 | 13:56h | UTCAtogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Cohort Study | Depression at any life stage linked to increased dementia incidence
2 Aug, 2023 | 13:49h | UTCAssociation of Early-, Middle-, and Late-Life Depression With Incident Dementia in a Danish Cohort – JAMA Neurology (link to abstract – $ for full-text)
Commentary: Depression Over Adulthood May Increase Risk of Dementia – Psychiatric News Alert
Review | First-line immunosuppression in neuromuscular diseases
1 Aug, 2023 | 14:09h | UTCFirst-line immunosuppression in neuromuscular diseases – Practical Neurology
Review | Multiple system atrophy
1 Aug, 2023 | 14:08h | UTCMultiple system atrophy – Practical Neurology
Review | Clinical assessment of parietal lobe function
1 Aug, 2023 | 14:03h | UTCClinical assessment of parietal lobe function – Practical Neurology
Review | Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology
31 Jul, 2023 | 14:07h | UTCNews Release: AAN issues guidance on new treatments for early Alzheimer’s disease – American Academy of Neurology
Phase 2 Trial | Oral orexin receptor 2 agonist shows promise in narcolepsy type 1, but raises hepatotoxic concerns
28 Jul, 2023 | 14:09h | UTCOral Orexin Receptor 2 Agonist in Narcolepsy Type 1 – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In a randomized trial involving patients with narcolepsy, an oral orexin receptor 2 agonist reduced sleepiness and cataplexy but had liver toxic effects. Read the full trial results: https://t.co/Go7lmQTu62
— NEJM (@NEJM) July 26, 2023
RCT – 2ry Analysis | Elevated intracranial bleeding risk with low-dose aspirin in older adults
27 Jul, 2023 | 13:09h | UTCSee also: Visual Abstract
News Release: Low dose aspirin won’t help some older adults trying to avoid a stroke: study – Monash University
Commentary: Daily aspirin doesn’t prevent strokes in older, healthy people after all – The Conversation
Original Study: Randomized Trial: Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
Related Guideline: USPSTF Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease.
Related Randomized Trials:
Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease
Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes
Related Meta-Analysis:
Meta-Analysis: Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events
Related Opinions:
Aspirin for Primary Prevention: Is This the End of the Road?
Evidence evolving on aspirin as prevention – ACP Internist
#347 USPSTF Update: Aspirin for Primary Prevention of CVD – The Curbsiders
Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness
26 Jul, 2023 | 13:28h | UTC
RCT | Vitamin D supplementation shows no cognitive benefit in mild cognitive impairment intervention
25 Jul, 2023 | 14:00h | UTCCommentary: Exercise and Cognitive Training Slow Thinking Declines. Vitamin D? Not So Much – HealthDay
Related:
RCT | No statistically significant impact of vitamin D on major cardiovascular events
2ry analysis of a RCT | Vitamin D supplementation does not affect cognitive function in older adults
Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention
Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases
Global, regional, and national burden of meningitis and its etiologies, 1990–2019
25 Jul, 2023 | 13:55h | UTC
Commentary on Twitter
Although largely preventable, meningitis still causes hundreds of thousands of deaths globally each year.
New @IHME_UW #GBDStudy in @TheLancetNeuro assesses incident cases and deaths due to acute infectious meningitis by aetiology and age from 1990–2019. https://t.co/S3KtMA7DMs pic.twitter.com/AYuSJHsNwK
— The Lancet (@TheLancet) July 20, 2023
Systematic Review | Existing research on post-stroke depression interventions lacks conclusive results
25 Jul, 2023 | 13:37h | UTC
RCT | Hearing intervention fails to impact 3-year cognitive decline in older adults
20 Jul, 2023 | 11:09h | UTCHearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
#AAIC23 While hearing aids did not have an impact on cognitive decline over 3 years in a general population, treating hearing loss protected against cognitive decline in older adults at greater risk of dementia, finds a new trial: https://t.co/1UjGgDf5m5 pic.twitter.com/kuujeekCWW
— The Lancet (@TheLancet) July 18, 2023
Prospective Study | Intelligence likely remains intact after pediatric concussion
20 Jul, 2023 | 11:06h | UTCIQ After Pediatric Concussion – Pediatrics (free for a limited period)
Commentaries:
IQ After Pediatric Concussion: Clinical Considerations – Pediatrics
No Evidence Seen for Differences in IQ After Pediatric Concussion – HealthDay
Concussions do not affect IQ in children, study finds – News Medical
RCT | Ischemic stroke patients benefit from Panax notoginseng saponins therapy
20 Jul, 2023 | 10:57h | UTCSee also: Visual Abstract
Review | Painful diabetic peripheral neuropathy
20 Jul, 2023 | 10:53h | UTC
RCT | Solanezumab fails to slow cognitive decline in preclinical Alzheimer’s disease
19 Jul, 2023 | 14:26h | UTCTrial of Solanezumab in Preclinical Alzheimer’s Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Related:
RCT | Donanemab slows early symptomatic Alzheimer’s progression, but raises serious safety concerns
RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns
Commentary on Twitter
Original Article: Trial of Solanezumab in Preclinical Alzheimer’s Disease (A4 trial) https://t.co/lCXsVoiP8i #AAIC23 pic.twitter.com/e8DplR27yd
— NEJM (@NEJM) July 18, 2023
RCT | Donanemab slows early symptomatic Alzheimer’s progression, but raises serious safety concerns
18 Jul, 2023 | 13:51h | UTCDonanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial – JAMA (free for a limited period)
Editorials:
Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed? – JAMA (free for a limited period)
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease – JAMA (free for a limited period)
Ushering in a New Era of Alzheimer Disease Therapy – JAMA (free for a limited period)
See also: Visual Abstract
Commentary: Expert reaction to results from Eli Lilly on its anti-amyloid drug donanemab – Science Media Centre
Related: RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns.
Nationwide Cohort Study | Adolescent hypertension linked with increased stroke risk in young adulthood
18 Jul, 2023 | 13:49h | UTCCommentary: The Relationship Between Adolescent Hypertension and Stroke Risk After Age 40 Years – Neurology Advisor